Jeff Jensen MD/PhD

I want to congratulate @kyleeagen.bsky.social and lab on their new preprint showing NSD3 stabilizes BRD4::NUTM1 on chromatin and regulates chromatin folding. Maybe NSD3 therapeutics for NUT??? www.biorxiv.org/content/10.6...

Signalome-wide mapping of the NFκB pathway in T-cells reveals novel targets for immunotherapy https://www.biorxiv.org/content/10.64898/2026.02.16.706160v1

Retract Until Verified The Implausibly Large Effect in the Recent Time-of-Day Immunotherapy Trial

I would like to share this substack post discussing the recent phase 3 time of day dosing for immunotherapy (done in China, published in Nature Medicine): aaox2.substack.com/p/retract-un...
@nature.com merits a response

Beyond knowing how to advise patients, our infusion center is full every day. Maybe immunotherapy patients could go in first half of the day and chemo second half?

I shared it with our thoracic group and lots of concerns raised. I haven’t looked enough to have an opinion

Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial - Nature Medicine In this randomized phase 3 trial, patients with treatment-naive stage III–IV nonsmall cell lung cancer who received sintilimab or pembrolizumab in combination with chemotherapy early in the day (befor...

www.nature.com/articles/s41...

Our infusion center already struggles to fit patients in. How are we going to accommodate this?

Congratulations Dr. Jensen!

Shared PRAME epitopes are T-cell targets in NUT carcinoma Background NUT carcinoma is a rare but highly lethal solid tumor without an effective standard of care. NUT carcinoma is caused by bromodomain-containing NUTM1 fusion oncogenes, most commonly BRD4::NU...

Our latest research showing PRAME as a previously unrecognized therapeutic target in NUT carcinoma just dropped on JITC. Huge thanks to @sitcancer.bsky.social @benjamingvincent.bsky.social @alexr.bsky.social @unclineberger.bsky.social and so may others!!!

jitc.bmj.com/content/14/2...

@lizbwood.bsky.social I am an early career physician scientist @unclineberger.bsky.social we are trying to open PRAME immunotherapy trials and saw your work @sitcancer.bsky.social can we discuss???

@benjamingvincent.bsky.social @alexr.bsky.social

CD27 agonism enhances long-lived CD4 T cell vaccine responses critical for antitumor immunity CD27 agonism enhances vaccine-induced CD4 T cell responses, enabling durable antitumor immunity not entirely dependent on CD8 T cells.

Congratulations to Zachary Hartman and colleagues @dukecancer.bsky.social on their latest paper on CD27 agonists as adjuvants for vaccines. Very cool!

doi.org/10.1126/scii...

Science’s 2025 Breakthrough of the Year: The unstoppable rise of renewable energy Clean energy infrastructure is being deployed with unmatched scale and speed—and China is leading the way

I thought the breakthrough of the year was PRAME in NUT carcinoma but looks like renewables won instead www.science.org/content/arti...

Passed my American Board of Internal Medicine Medical Oncology boards. Woooooo

FDA grants traditional approval to tarlatamab-dlle for extensive stage On November 19, 2025, the Food and Drug Administration granted traditional approval to tarlatamab-dlle (Imdelltra, Amgen Inc.) for adults with extensive stage s

www.fda.gov/drugs/resour...
Great drug but dysgeusia a major draw back

CDK4/6 inhibition mitigates chemotherapy-induced expansion of TP53-mutant clonal hematopoiesis AbstractTherapy-related myeloid neoplasms (tMN) are a fatal consequence of exposure to oncologic therapy. Prior work has demonstrated that the expansion of

Another reason to love trilaciclib: less clonal hematopoiesis. Congratulations to Kelly Bolton Lab for a great study.

doi.org/10.1182/bloo...

Congrats @RashaCosman on late breaking oral presentation, showcasing safety and MOA of novel in vivo CAR targeting TROP2 expressing tumors #SITC25 @NECTANSW - led trial from 🇦🇺 👏.

This technology will expand access to solid tumor cell therapy 🌟

How much do you think all of that would cost

I am also unaffected by the TikTok ban